Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TmCD19-IL18 CAR T Cells in Relapsed or Refractory CD19+ Cancers
NCT05989204Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Nov 2023
- Primary completion
- Oct 2041
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of huCART19-IL18 in non-Hodgkin lymphoma (NHL) (5 arms), sponsored by University of Pennsylvania. Primary endpoints: Dose Limiting Toxicities at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Nov 2023; status: active, not recruiting.
02
Drugs
huCART19-IL18
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05989204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05989204.